Last reviewed · How we verify

NCT04091906

PBMC Donation in UCAR-T Cells

Status unknown NA Last updated 17 September 2019
What this trial tests

NA trial testing Peripheral blood mononuclear cell apheresis in Peripheral Blood Mononuclear Cell Donation in 20 participants. Status unknown.

Timeline
1 October 2019
Primary endpoint
31 March 2020
30 June 2020

Quick facts

Lead sponsorThe First Affiliated Hospital with Nanjing Medical University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment20
Start date1 October 2019
Primary completion31 March 2020
Estimated completion30 June 2020
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Who can join

Adults 18 to 40, any sex, with Peripheral Blood Mononuclear Cell Donation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Peripheral blood mononuclear cell donation protocol for tumor immunotherapy study of UCAR-T cells

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Peripheral blood mononuclear cell apheresis

Trials testing the same drug.

Other The First Affiliated Hospital with Nanjing Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04091906.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing